WORLD PEPTIDEFOUNDATION
An initiative of the World Peptide Foundation · Every experience matters

living literature

Research updates and alerts

Follow newly published governed evidence, regulatory records, and corrections. Draft, quarantined, and unresolved records do not appear here.

Subscribe with Atom/RSSEmail newsletterJSON feed
  1. Evidence added

    Vasopressin in septic shock: an individual patient data meta-analysis of randomised controlled trials.

    Vasopressin · 2019 · observational · DOI 10.1007/s00134-019-05620-2 · PMID 31062052

  2. Evidence added

    Lanreotide in metastatic enteropancreatic neuroendocrine tumors.

    Lanreotide · 2014 · phase_3 · DOI 10.1056/nejmoa1316158 · PMID 25014687

  3. Evidence added

    Prospective Randomized Pilot Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric Extracorporeal Membrane Oxygenation.

    Bivalirudin · 2025 · phase_1_2 · DOI 10.1097/pcc.0000000000003642 · PMID 39585174

  4. Evidence added

    Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

    Abaloparatide · 2023 · observational · DOI 10.7326/m22-0684 · PMID 36592455

  5. Evidence added

    Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials.

    Abaloparatide · 2023 · observational · DOI 10.1136/bmj-2021-068033 · PMID 37130601

  6. Evidence added

    Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.

    Teriparatide · 2015 · phase_1_2 · DOI 10.1016/s0140-6736(15)61120-5 · PMID 26144908

  7. Evidence added

    Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.

    Teriparatide · 2023 · observational · DOI 10.7326/m22-0684 · PMID 36592455

  8. Evidence added

    Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.

    Leuprolide · 2023 · phase_3 · DOI 10.1056/nejmoa2303974 · PMID 37851874

  9. Regulatory record

    Vasopressin — Canada (Health Canada — Vasopressin Injection USP DIN 02139502)

    Health Canada — Importation of US-Authorized Vasopressin Injection during Canadian shortage

  10. Regulatory record

    Vasopressin — United States (FDA — VASOSTRICT)

    FDA Drugs@FDA — VASOSTRICT NDA 204485

  11. Evidence added

    Intra-arterial vasopressin in the human forearm: pharmacodynamics and the role of nitric oxide.

    Vasopressin · 2003 · phase_1_2 · DOI 10.1016/s0009-9236(03)00065-1 · PMID 12844130

  12. Evidence added

    Vasopressin does not raise cardiac enzymes following cardiac surgery: a randomized double-blind clinical trial.

    Vasopressin · 2015 · phase_1_2 · DOI 10.1053/j.jvca.2014.07.007 · PMID 25440643

  13. Evidence added

    Comparing two different arginine vasopressin doses in advanced vasodilatory shock: a randomized, controlled, open-label trial.

    Vasopressin · 2010 · phase_1_2 · DOI 10.1007/s00134-009-1630-1 · PMID 19756505

  14. Evidence added

    Controlled trial of vasopressin and balloon tamponade in bleeding esophageal varices.

    Vasopressin · 1984 · phase_1_2 · DOI 10.1002/hep.1840040515 · PMID 6383998

  15. Evidence added

    Cutaneous vascular reactivity and flow motion response to vasopressin in advanced vasodilatory shock and severe postoperative multiple organ dysfunction syndrome.

    Vasopressin · 2006 · phase_1_2 · DOI 10.1186/cc4845 · PMID 16542484

  16. Evidence added

    Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial.

    Vasopressin · 2006 · phase_1_2 · DOI 10.1007/s00134-006-0378-0 · PMID 17019548

  17. Evidence added

    Intraarterial vasopressin in the treatment of upper gastrointestinal hemorrhage: a prospective, controlled clinical trial.

    Vasopressin · 1975 · phase_1_2 · PMID 803910

  18. Evidence added

    Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials.

    Vasopressin · 2024 · observational · DOI 10.1186/s13054-024-05212-7 · PMID 39736782

  19. Evidence added

    Dilute versus concentrated vasopressin administration during laparoscopic myomectomy: a randomised controlled trial.

    Vasopressin · 2017 · phase_1_2 · DOI 10.1111/1471-0528.14179 · PMID 27362908

  20. Evidence added

    Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial.

    Vasopressin · 2016 · phase_1_2 · DOI 10.1001/jama.2016.10485 · PMID 27483065

  21. Evidence added

    Vasopressors for the Treatment of Septic Shock: Systematic Review and Meta-Analysis.

    Vasopressin · 2015 · observational · DOI 10.1371/journal.pone.0129305 · PMID 26237037

  22. Evidence added

    Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial.

    Vasopressin · 2017 · phase_1_2 · DOI 10.1097/aln.0000000000001434 · PMID 27841822

  23. Evidence added

    Vasopressin Versus Norepinephrine for the Management of Septic Shock in Cancer Patients: The VANCS II Randomized Clinical Trial.

    Vasopressin · 2019 · phase_1_2 · DOI 10.1097/ccm.0000000000004023 · PMID 31609774

  24. Evidence added

    Reduction of norepinephrine versus vasopressin in the stabilization phase of septic shock: RENOVA clinical trial.

    Vasopressin · 2025 · phase_1_2 · DOI 10.1016/j.medine.2025.502147 · PMID 39890531

  25. Evidence added

    Vasopressin versus norepinephrine infusion in patients with septic shock.

    Vasopressin · 2008 · phase_1_2 · DOI 10.1056/nejmoa067373 · PMID 18305265

  26. Evidence added

    THE EFFICACY AND SAFETY OF VASOPRESSORS FOR SEPTIC SHOCK PATIENTS: A SYSTEMIC REVIEW AND NETWORK META-ANALYSIS.

    Vasopressin · 2023 · observational · DOI 10.1097/shk.0000000000002193 · PMID 37548686

  27. Evidence added

    Comparison of intramyometrial vasopressin plus rectal misoprostol with intramyometrial vasopressin alone to decrease blood loss during laparoscopic myomectomy: Randomized clinical trial.

    Vasopressin · 2018 · phase_1_2 · DOI 10.1016/j.ejogrb.2018.07.006 · PMID 30056355

  28. Evidence added

    A randomized comparison of vasopressin and tourniquet as hemostatic agents during myomectomy.

    Vasopressin · 1996 · phase_1_2 · DOI 10.1016/0029-7844(96)00071-3 · PMID 8649682

  29. Evidence added

    A double-blind randomized trial: prophylactic vasopressin reduces hypotension after cardiopulmonary bypass.

    Vasopressin · 2003 · phase_1_2 · DOI 10.1016/s0003-4975(02)04408-9 · PMID 12645718

  30. Evidence added

    Pilot safety study of low-dose vasopressin in non-septic critically ill children.

    Vasopressin · 2009 · phase_1_2 · DOI 10.1007/s00134-008-1392-1 · PMID 19132338

  31. Evidence added

    Safety and Efficacy of Vasopressin After Fontan Completion: A Randomized Pilot Study.

    Vasopressin · 2019 · phase_1_2 · DOI 10.1016/j.athoracsur.2019.06.053 · PMID 31400337

  32. Evidence added

    Vasopressin in pediatric vasodilatory shock: a multicenter randomized controlled trial.

    Vasopressin · 2009 · phase_1_2 · DOI 10.1164/rccm.200902-0221oc · PMID 19608718

  33. Regulatory record

    Teriparatide — United States (FDA — BONSITY)

    FDA Drugs@FDA — BONSITY NDA 211939

  34. Regulatory record

    Teriparatide — United States (FDA — FORTEO)

    FDA Drugs@FDA — FORTEO NDA 021318

  35. Regulatory record

    Oxytocin — United States (FDA — PITOCIN)

    FDA Drugs@FDA — PITOCIN NDA 018261

  36. Regulatory record

    Oxytocin — United States (FDA — OXYTOCIN injection)

    FDA Drugs@FDA — OXYTOCIN NDA 018248

  37. Regulatory record

    Octreotide — United States (FDA — MYCAPSSA)

    FDA Drugs@FDA — MYCAPSSA NDA 208232

  38. Regulatory record

    Octreotide — United States (FDA — SANDOSTATIN LAR DEPOT)

    FDA Drugs@FDA — SANDOSTATIN LAR DEPOT NDA 021008

  39. Regulatory record

    Leuprolide — United States (FDA — LUPRON DEPOT)

    FDA Drugs@FDA — LUPRON DEPOT NDA 019943

  40. Regulatory record

    Leuprolide — United States (FDA — LUPRON DEPOT-PED)

    FDA Drugs@FDA — LUPRON DEPOT-PED NDA 020263